Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

EBMT 2019 | LentiGlobin BB305 for β-Thalassemia

Christian Chabannon • 26 Mar 2019
EBMT 2019
Non-Malignant Thalassemia LentiGlobin BB305

In this video, Christian Chabannon, MD, PhD, of Institut Paoli-Calmettes, Marseille, France, speaks about LentiGlobin BB305 for β-Thalassemia. Prof. Chabannon was talking at the European Society for Blood and Marrow Transplantation (EBMT) 2019 Annual Meeting, held in Frankfurt, Germany.

More from Christian Chabannon

1:53
Preclinical research for the future of cellular therapies
Christian Chabannon • 16 Apr 2024
1:54
Work of the WBMT to improve access to advanced cancer therapies
Christian Chabannon • 16 Apr 2024
1:41
The consequences of regulatory changes on access to devices and reagents needed for graft processing
Christian Chabannon • 16 Apr 2024
2:17
Improving access to advanced therapies: the access to CAR-T in Europe
Christian Chabannon • 17 Feb 2024

Related Videos

2:27
Optimizing the delivery of care for patients with hemoglobinopathies in the UK
Farrukh Shah • 30 Apr 2024
1:06
The importance of shared-decision making when treating infants with hemophilia
Jayashree Motwani • 28 Apr 2024
2:24
Primary prevention against atherosclerosis in patients with hemophilia
Beverley Hunt • 29 Apr 2024
2:40
The safety & efficacy of emicizumab in patients under 18 months with hemophilia A
Eman Hassan • 28 Apr 2024
The content of VJHemOnc is intended for healthcare professionals